Skip to Content

Clinical Data from 'OPEN I' Study of the Stentys Stent to Be Reported at Next Week's 'TCT 2008' International Cardiovascular Meeting

PARIS--(BUSINESS WIRE)--Oct 9, 2008 - Medical device pioneer Stentys announced today that clinical results from the 'OPEN I' clinical study using its bifurcated stent will be presented at next week's Transcatheter Cardiovascular Therapeutics ('TCT') 2008 symposium, an international medical meeting on cardiovascular intervention. The clinical data -- to be presented by Stefan Verheye, M.D., Department of Cardiology, Middelheim, Antwerp, Belgium -- will look at safety after 30 days post-implantation of the Stentys bifurcated stent in a total of 40 patients.

Dr. Verheye will make his Stentys presentation at TCT 2008 on Monday, Oct. 13, 2:50 p.m., at the Washington D.C. Convention Center.

The annual TCT medical symposium has become the primary means by which state-of-the-art techniques and training are disseminated to interventionalists around the world, allowing them to bring innovative breakthroughs to their practices and dramatically improve the lives of their patients with cardiovascular disease.

About Stentys

Based in Paris, Stentys intends to make treatment of blocked coronary artery bifurcations as simple and effective as a conventional stenting procedure. The Company has developed the world's first next-generation dedicated stent for treatment of blocked coronary artery bifurcations that is designed so that hundreds of thousands of patients might avoid open-chest surgery. To date, the Stentys bifurcated stent has been successfully implanted in patients as part of the OPEN 1 trial, taking routine interventional time to complete; the patients were released from the ICU within hours of implantation of the Stentys bifurcated stent and were discharged from the hospital shortly after the procedure.


Ronald Trahan Associates Inc.
Ronald C. Trahan, APR, +1-508-359-4005

Posted: October 2008